These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23358123)

  • 21. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
    Russell-Jones D; Cuddihy RM; Hanefeld M; Kumar A; González JG; Chan M; Wolka AM; Boardman MK;
    Diabetes Care; 2012 Feb; 35(2):252-8. PubMed ID: 22210563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks.
    Diamant M; Van Gaal L; Stranks S; Guerci B; MacConell L; Haber H; Scism-Bacon J; Trautmann M
    Diabetes Care; 2012 Apr; 35(4):683-9. PubMed ID: 22357185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.
    Buse JB; Garber A; Rosenstock J; Schmidt WE; Brett JH; Videbæk N; Holst J; Nauck M
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1695-702. PubMed ID: 21450987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
    Wysham C; Blevins T; Arakaki R; Colon G; Garcia P; Atisso C; Kuhstoss D; Lakshmanan M
    Diabetes Care; 2014 Aug; 37(8):2159-67. PubMed ID: 24879836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.
    Fineman M; Flanagan S; Taylor K; Aisporna M; Shen LZ; Mace KF; Walsh B; Diamant M; Cirincione B; Kothare P; Li WI; MacConell L
    Clin Pharmacokinet; 2011 Jan; 50(1):65-74. PubMed ID: 21142268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of glucagon-like peptide-1 receptor agonist combined with sodium-glucose co-transporter-2 inhibitor in the treatment of type 2 diabetes mellitus patients with obesity: a retrospective analysis study.
    Wang J; Chen Y; Lu Y; Wang H; Zhao Y
    Am J Transl Res; 2023; 15(4):2949-2956. PubMed ID: 37193156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exenatide extended-release: a review of its use in type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2012 Aug; 72(12):1679-707. PubMed ID: 22867046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial.
    Kelly AS; Rudser KD; Nathan BM; Fox CK; Metzig AM; Coombes BJ; Fitch AK; Bomberg EM; Abuzzahab MJ
    JAMA Pediatr; 2013 Apr; 167(4):355-60. PubMed ID: 23380890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials.
    Macconell L; Brown C; Gurney K; Han J
    Diabetes Metab Syndr Obes; 2012; 5():29-41. PubMed ID: 22375098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries.
    Divino V; DeKoven M; Hallinan S; Varol N; Wirta SB; Lee WC; Reaney M
    Diabetes Ther; 2014 Dec; 5(2):499-520. PubMed ID: 25366334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
    Lundkvist P; Pereira MJ; Katsogiannos P; Sjöström CD; Johnsson E; Eriksson JW
    Diabetes Obes Metab; 2017 Sep; 19(9):1276-1288. PubMed ID: 28345814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Corrigendum to "Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury" [Neurobiology of Disease Volume 124 (2019) 439-453 /YNBDI_4338].
    Bader M; Li Y; Lecca D; Rubovitch V; Tweedie D; Glotfelty E; Rachmany L; Kim HK; Choi HI; Hoffer BJ; Pick CG; Greig NH; Kim DS
    Neurobiol Dis; 2024 Sep; 199():106563. PubMed ID: 38890024
    [No Abstract]   [Full Text] [Related]  

  • 34. Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.
    Wysham CH; MacConell LA; Maggs DG; Zhou M; Griffin PS; Trautmann ME
    Mayo Clin Proc; 2015 Mar; 90(3):356-65. PubMed ID: 25744115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
    Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME
    Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of cardiovascular disease: the effects of diabetes and anti-diabetic drugs - a nested case-control study.
    Gejl M; Starup-Linde J; Scheel-Thomsen J; Gregersen S; Vestergaard P
    Int J Cardiol; 2015 Jan; 178():292-6. PubMed ID: 25465309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dapagliflozin in patients with type 2 diabetes mellitus.
    Filippatos TD; Liberopoulos EN; Elisaf MS
    Ther Adv Endocrinol Metab; 2015 Feb; 6(1):29-41. PubMed ID: 25678954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study.
    Charles ED; Neuschwander-Tetri BA; Pablo Frias J; Kundu S; Luo Y; Tirucherai GS; Christian R
    Obesity (Silver Spring); 2019 Jan; 27(1):41-49. PubMed ID: 30520566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the incretin system in obesity and type 2 diabetes mellitus.
    Ansari S; Khoo B; Tan T
    Nat Rev Endocrinol; 2024 Aug; 20(8):447-459. PubMed ID: 38632474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.